High Flow Nasal Cannula Market

Growing respiratory cases are driving the market growth

The market CAGR for high-flow nasal cannulas is growing because of the increasing prevalence of respiratory conditions such as asthma, sleep apnea, and COPD. Asthma and sleeping disorders frequently interrupt breathing during sleep. Nasal cannulas are included in the treatment when CPAP therapy is advised for sleep apnea. A survey conducted among individuals aged 30-70 from 164 countries found that 202,157,057 out of 1,513,628,587 females (13.4%) globally have mild SA, as reported in a March 2023 Oxford Academics article.

Moderate SA affects 14.6%, 15.3% and 10.6% of wealthy females, moderately affluent females and somewhat affluent females, respectively, while affecting 23.5, 18.3% and 16.3% of wealthy males, moderately affluent males and somewhat affluent males; therefore, it’s expected that adult sleep apnea will continue to increase leading to higher needs for nasal cannulas thus driving up CAGR in high flow nasal cannula market.

Due to an aging populace, there will be a rapid increase in future growth rates within this industry; seniors are defined as anyone aged over 65 years old, and they account for most patients but not all who require acute care services such as nursing homes, etc. A high-flow oxygen therapy system can be used safely and effectively among elderly patients with acute respiratory failure when conventional methods fail to elicit a response, or noninvasive ventilation (NIV) cannot be tolerated due to intolerance or contraindication against it without meeting criteria for intensive care unit (ICU) admission.

Consumer demand for high-flow nasal cannulas is rising because respiratory ailments, including asthma, sleep apnea, and COPD, are becoming more common, thus expanding the market. November of 2022 saw a significant moment in England and Wales’s demographic history when the number of people aged 65 and over, reached 11 million, accounting for 18.6% of the total population, according to the National Statistical Institute of UK and Office for National Statistics. The intriguing thing about this group is that there were more than half a million elderly persons — specifically 527900.

Hence, we are now experiencing a high demand for high-flow nasal cannulas due to the increasing number of old people.

An increasing need for high-flow nasal cannulas is expected with wider corporate initiatives and more acceptance towards different business strategies such as partnerships, collaborations, or product launches, which will drive expansion in this industry; an example can be seen during March 2020 when Masimo – a global leader in noninvasive monitoring technologies – acquired TNI Medical AG; an innovative ventilator manufacturer based at Würzburg, Germany. This strategic acquisition has the potential to greatly benefit Masimo's lineup of products.

Masimo aims to expand the use of its technology in a growing worldwide market, particularly in the area of nasal insufflation therapy, by leveraging TNI's vast engineering and commercial expertise. Thus, driving the high-flow nasal cannula market revenue.

The Global High-Flow Nasal Cannula Market Industry is poised for substantial growth, with projections indicating a market size of 8.9 USD Billion in 2024 and an anticipated increase to 30.3 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 11.78% from 2025 to 2035, reflecting the increasing adoption of high-flow nasal cannulas in various healthcare settings. The market dynamics are influenced by factors such as rising respiratory disease prevalence, technological advancements, and expanding healthcare infrastructure, all contributing to a favorable environment for market expansion.

The Global High-Flow Nasal Cannula Market Industry experiences a notable increase in demand for oxygen therapy, driven by the rising prevalence of respiratory diseases. Conditions such as chronic obstructive pulmonary disease and asthma are becoming more common, necessitating effective oxygen delivery systems. In 2024, the market is projected to reach 8.9 USD Billion, reflecting the growing recognition of high-flow nasal cannulas as a preferred method for oxygen therapy. This trend is likely to continue as healthcare providers increasingly adopt these devices for their ability to deliver precise oxygen concentrations and improve patient outcomes.

The expansion of healthcare infrastructure, particularly in developing regions, is a significant driver for the Global High-Flow Nasal Cannula Market Industry. As countries invest in improving healthcare facilities and access to advanced medical technologies, the demand for high-flow nasal cannulas is expected to rise. This trend is particularly evident in regions where respiratory diseases are prevalent, and healthcare systems are evolving to meet the needs of the population. The projected growth of the market to 30.3 USD Billion by 2035 underscores the potential for increased adoption of these devices as healthcare access improves globally.

Innovations in the design and functionality of high-flow nasal cannulas are propelling the Global High-Flow Nasal Cannula Market Industry forward. Recent advancements include the development of more comfortable and user-friendly devices that enhance patient compliance. For instance, the integration of heated and humidified oxygen delivery systems has been shown to improve patient comfort and reduce complications. As these technologies evolve, they are expected to capture a larger market share, potentially contributing to the projected growth of the market to 30.3 USD Billion by 2035. This continuous evolution in design reflects the industry's commitment to improving therapeutic efficacy.

There is a growing awareness of non-invasive ventilation techniques among healthcare professionals and patients, which is positively impacting the Global High-Flow Nasal Cannula Market Industry. High-flow nasal cannulas are increasingly recognized for their effectiveness in managing respiratory distress without the need for invasive procedures. This trend is likely to drive market growth as more clinicians adopt these devices in various clinical settings. The anticipated compound annual growth rate of 11.78% from 2025 to 2035 indicates a robust market expansion, as healthcare systems prioritize non-invasive solutions to enhance patient care.

Regulatory bodies are increasingly supportive of innovative medical devices, which is beneficial for the Global High-Flow Nasal Cannula Market Industry. Streamlined approval processes and favorable regulations encourage manufacturers to develop and introduce new high-flow nasal cannula products. This regulatory environment fosters innovation and competition, leading to a wider range of options for healthcare providers. As a result, the market is likely to see significant growth, with projections indicating a rise to 30.3 USD Billion by 2035. This supportive regulatory landscape is crucial for the ongoing advancement of respiratory care technologies.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The largest market share of the high-flow nasal cannula industry will come from the North American region mainly because it houses some top-performing markets globally. The reason behind its success lies in several factors. Firstly, there has been a rise in usage rates associated with these devices due to a higher number of recorded cases related to sleep apnea syndrome among people living on this side, which also happens to be one major cause of them being diagnosed with COPD.

Secondly, the availability of advanced healthcare systems where even the most complex surgeries can be done successfully coupled up favorable reimbursement policies implemented by different governments over the years, making it easily affordable for patients to seek medical attention whenever required, thus leading to the dominance this particular industry across the United States among other countries around the world at large.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: HIGH-FLOW NASAL CANNULA SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe high-flow nasal cannula market accounts for the second-largest market share. Anticipated advancements in the region are expected to be propelled by a rise in respiratory diseases, increased recognition of the benefits of high-flow nasal cannula therapy, and a growing approval of noninvasive ventilation techniques. The industry is growing because of the large market leaders in the region. Further, the German high-flow nasal cannula market held the largest market share, and the UK high-flow nasal cannula market was the fastest growing market in the European region.

The Asia-Pacific High-Flow Nasal Cannula Market is expected to grow at the fastest CAGR from 2024 to 2032. The large and rapidly growing population with COPD and asthma, increasing the overall number of patients with respiratory illnesses and oxygen therapy needs, is one of many factors influencing the projected growth rate. Moreover, China’s high-flow nasal cannula market held the largest market share, and the Indian high-flow nasal cannula market was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the high-flow nasal cannula market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the high-flow nasal cannula industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global high-flow nasal cannula industry to benefit clients and increase the market sector. In recent years, the high-flow nasal cannula industry has offered some of the most significant advantages to medicine. Major players in the high-flow nasal cannula market are attempting to increase market demand by investing in research and development operations, including Fisher & Paykel Healthcare Limited, Teleflex Incorporated, ResMed, Devatec, Smiths Medical, Vapotherm, Hamilton Medical, Masimo (TNI medical AG), Flexicare Medical Limited, and Great Group Medical Co. Ltd.

With an emphasis on critical care, safety devices, and drug distribution, Smiths Medical produces medical equipment used in a range of therapeutic, diagnostic, and surgical procedures. The company's product line includes products for pain management, infusion devices, diabetes solutions, temperature management systems, drainage systems, respiratory systems, interventional imaging systems, safety solutions, anesthesia airway systems, tracheostomy products, vascular access devices, and ventilation systems.

Medical equipment is developed, manufactured, and distributed by ResMed Inc. (ResMed). The company provides its goods and services for the identification, therapy, and control of respiratory conditions, including chronic obstructive pulmonary disease (COPD), sleep apnea, and sleep-disordered breathing (SDB). Its main products are ventilation products, accessories, diagnostic products, masks, headgear, motors, and data/patient management products. Airflow generators include continuous positive airway pressure (CPAP), auto-bilevel, automatic positive airway pressure (APAP), variable positive airway pressure (VPAP), humidifiers, and ventilation products. ResMed Inc. announced the release of the AirSenseTM 11 device in 2021, which offers patients experiencing respiratory distress high-flow oxygen therapy.

The new gadget is made to be both easy to use and adaptable to each patient's unique demands.